Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

The 2019 annual conferences of the American Society of Clinical Oncology and the European Hematology Association befell, respectively, in Chicago, Illinois, 31 May-4 June, and in Amsterdam, Netherlands, 13-16 June. At the conferences, outcomes from key research on the remedy of sufferers with relapsed or refractory multiple myeloma with high-risk cytogenetics had been introduced. Our assembly report describes these research … Read more